Murdo Gordon - Net Worth and Insider Trading
Murdo Gordon Net Worth
The estimated net worth of Murdo Gordon is at least $12 Million dollars as of 2023-10-05. Murdo Gordon is the EVP, Global Commercial Ops of Amgen Inc and owns about 44,308 shares of Amgen Inc (AMGN) stock worth over $12 Million. Details can be seen in Murdo Gordon's Latest Holdings Summary section.
Transaction Summary of Murdo Gordon
Murdo Gordon Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Murdo Gordon owns 2 companies in total, including Amgen Inc (AMGN) , and Bristol-Myers Squibb Co (BMY) .
Click here to see the complete history of Murdo Gordon’s form 4 insider trades.
Insider Ownership Summary of Murdo Gordon
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
AMGN | Amgen Inc | 2018-09-03 | EVP Global Commercial Ops |
BMY | Bristol-Myers Squibb Co | 2015-05-05 | SVP & Head of Worldwide Markets |
Murdo Gordon Latest Holdings Summary
Murdo Gordon currently owns a total of 1 stock. Murdo Gordon owns 44,308 shares of Amgen Inc (AMGN) as of August 10, 2023, with a value of $12 Million.
Murdo Gordon Form 4 Trading Tracker
According to the SEC Form 4 filings, Murdo Gordon has made a total of 1 transactions in Amgen Inc (AMGN) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Amgen Inc is the sale of 9,558 shares on August 10, 2023, which brought Murdo Gordon around $3 Million.
Insider Trading History of Murdo Gordon
- 1
Murdo Gordon Trading Performance
Murdo Gordon Ownership Network
Ownership Network List of Murdo Gordon
Ownership Network Relation of Murdo Gordon
Murdo Gordon Owned Company Details

What does Amgen Inc do?
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Who are the key executives at Amgen Inc?
Murdo Gordon is the EVP Global Commercial Ops of Amgen Inc. Other key executives at Amgen Inc include VP & Finance & CAO Matthew C. Busch , SVP & Human Resources Derek Miller , and SVP & Business Development Rachna Khosla .
Amgen Inc (AMGN) Insider Trades Summary
Over the past 18 months, Murdo Gordon made 1 insider transaction in Amgen Inc (AMGN) with a net sale of 9,558. Other recent insider transactions involving Amgen Inc (AMGN) include a net sale of 800 shares made by R Sanders Williams , a net sale of 13,500 shares made by Jonathan P Graham , and a net sale of 6,600 shares made by Robert Eckert .
In summary, during the past 3 months, insiders sold 9,558 shares of Amgen Inc (AMGN) in total and bought 0 shares, with a net sale of 9,558 shares. During the past 18 months, 31,390 shares of Amgen Inc (AMGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 31,390 shares.
Amgen Inc (AMGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Amgen Inc Insider Transactions
Murdo Gordon Mailing Address
Above is the net worth, insider trading, and ownership report for Murdo Gordon. You might contact Murdo Gordon via mailing address: C/o Bristol-myers Squibb Company, 345 Park Ave, New York Ny 10154.